Congressional Committee Launches Investigation of Big Three PBMs’ Business Practices

A little more than a year after Rep. James Comer (R-Ky.), then-ranking member of the House Committee on Oversight and Reform, released a report on PBMs’ business practices and their negative impact on drug prices, patients’ health and market competition, the now-Chairman Comer revealed that he is launching an investigation into those practices. The move continues to keep pressure on the entities over some of their practices and lack of transparency amid concerns around prescription drug prices.

On March 1, Comer sent letters to senior officials at the Office of Personnel Management (OPM), Defense Health Agency (DHA) and CMS, as well as to the three largest PBMs — Cigna Corp.’s Express Scripts, CVS Health Corp.’s Caremark and UnitedHealth Group’s Optum Rx — requesting a trove of documents and communications.

© 2024 MMIT
Angela Maas

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

capitol-dome
March 2

Senate Hearing Continues Government Focus on PBM Industry

Read More
pills-and-bottle
July 14

FTC Reveals PBM Investigation, Issues Policy Statement Targeting Rebates

READ MORE
interior-of-CVS-pharmacy
July 7

As PBMs Are Under Microscope, New Suit Accuses CVS of Generics-Blocking Scheme

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today